Titan Medical Inc. (T:TMD)
Business Focus: Advanced Medical Equipment & Technology (NEC)
| Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
| Company Contact | |
| Address: | 155 University Avenue, Suite 750 TORONTO ON M5H 3B7 |
| Tel: | N/A |
| Website: | https://www.titanmedicalinc.com |
| IR: | See website |
| Key People | ||
| Paul G. Cataford Chairman of the Board, Interim President and Chief Executive Officer | Stephen Lemieux Chief Financial Officer | Chien Huang Vice President - Finance |
| Bill Fahey Vice President - Manufacturing and Operations | Jasminder Brar Vice President - Legal and IP, General Counsel, Corporate Secretary | Deepak Basra Vice President - Strategy and Business Development |
| Business Overview |
| Titan Medical Inc. is a medical technology company. The Company is focused on the development and commercialization of surgical technologies for single access robotic assisted surgery (RAS) requiring only a single patient access point. It has integrated technology into the Enos surgical system with the purpose of enhancing the robotic assisted surgical experience for surgeons. The Enos surgeon workstation includes a three dimensional (3D) high-definition display to provide a crucial balance of surgical immersion and situational awareness in the operating room. The display is mounted to the ergonomic workstation with a natural handle interface designed to deliver and support comfortable surgical posture, even during long procedures. The Company's multi-articulated instruments bring fluid flexibility and strength to position the end effectors for grasping, suturing, cutting and coagulation. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Titan Medical Inc revenues increased from $0K to $17.6M. Net income totaled $7M vs. loss of $42.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Dep of Fin Lease Right-of-Use Assets decrease from $405K (expense) to $0K, Depreciation of PPE decrease from $302K (expense) to $0K. |
| Employees: | 4 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | N/A |
| Annual revenue (TTM): | $24.16M as of Dec 31, 2023 |
| EBITDA (TTM): | $12.51M as of Dec 31, 2023 |
| Net annual income (TTM): | $9.53M as of Dec 31, 2023 |
| Free cash flow (TTM): | $6.12M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 114,039,850 as of Mar 1, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
